Holen Sie sich die Stockscreener-App
1.28
4.07%
0.05
Handel nachbörslich:
1.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTSO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.23
Offen:
$1.27
24-Stunden-Volumen:
104.59K
Relative Volume:
1.08
Marktkapitalisierung:
$66.37M
Einnahmen:
$33.79M
Nettoeinkommen (Verlust:
$-18.67M
KGV:
-3.5734
EPS:
-0.3582
Netto-Cashflow:
$-19.17M
1W Leistung:
+1.59%
1M Leistung:
+52.38%
6M Leistung:
+40.66%
1J Leistung:
+82.08%
1-Tages-Spanne:
$1.245
$1.30
1-Wochen-Bereich:
$1.10
$1.39
52-Wochen-Spanne:
$0.70
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Firmenname
Cytosorbents Corp
Sektor
Branche
Telefon
973-329-8885
Adresse
305 COLLEGE ROAD EAST, PRINCETON, NJ
Vergleichen Sie CTSO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
1.28 | 66.37M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
136.01 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
107.41 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.63 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.21 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-07 | Eingeleitet | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2020-09-17 | Eingeleitet | Jefferies | Buy |
| 2020-09-01 | Eingeleitet | SVB Leerink | Outperform |
| 2017-08-08 | Bestätigt | Maxim Group | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-05-24 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | Bestätigt | MLV & Co | Buy |
| 2015-04-01 | Bestätigt | MLV & Co | Buy |
| 2015-03-05 | Eingeleitet | MLV & Co | Buy |
| 2015-02-25 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-01-27 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Cytosorbents Corp Aktie (CTSO) Neueste Nachrichten
Millennium Management LLC Buys Shares of 33,280 Cytosorbents Co. (NASDAQ:CTSO) - Defense World
Cytosorbents announces voting results from annual meeting By Investing.com - Investing.com Canada
Cytosorbents announces voting results from annual meeting - Investing.com
CytoSorbents Warrants Expire Worthless as Stock Price Fails Threshold - Investing.com
Cytosorbents Co. (NASDAQ:CTSO) Shares Purchased by Northern Trust Corp - Defense World
Critical Care Leader CytoSorbents Reveals Growth Strategy at Jefferies Healthcare Conference - Stock Titan
Cytosorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented At EuroPCR 2025 - marketscreener.com
CytoSorbents device cuts bleeding in CABG patients - Investing.com
New Clinical Data: How CytoSorbents' Breakthrough Device Slashes Severe Bleeding Risk in Urgent Heart Surgery - Stock Titan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - Defense World
Cytosorbents FY2025 EPS Forecast Lifted by HC Wainwright - Defense World
D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Earns Neutral Rating from HC Wainwright - Defense World
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents Corp’s Earnings Call: A Balanced Outlook - TipRanks
CytoSorbents (CTSO) Receives Neutral Rating from HC Wainwright & Co. | CTSO Stock News - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | CTSO Stock News - GuruFocus
CytoSorbents: Q1 Earnings Snapshot - CT Insider
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and Strengthening Financials - GuruFocus
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents (CTSO) Targets Growth Amid Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents Q1 2025 misses earnings, stock dips - Investing.com
CytoSorbents Corp Q1 2025 Earnings: EPS of -$0.06 Beats Estimate, Revenue of $8.7M Misses Estimate - GuruFocus
CTSO Reports Q1 Revenue Below Expectations Amid Strategic Changes in Germany | CTSO Stock News - GuruFocus
CytoSorbents Corporation Q1 2025 Financial Results - TradingView
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Transcript : Cytosorbents Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Raymond James Financial Inc. Makes New Investment in Cytosorbents Co. (NASDAQ:CTSO) - Defense World
CytoSorbents Corp (CTSO) Q1 2025 Earnings Report Preview: What t - GuruFocus
CytoSorbents's Earnings: A Preview - Nasdaq
CytoSorbents Corp (CTSO) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Cytosorbents (CTSO) Projected to Post Earnings on Wednesday - Defense World
Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
CytoSorbents (CTSO) Stock: Analyst Maintains "Buy" Rating with $ - GuruFocus
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Today’s watch list includes Cytosorbents Corp (NASDAQ:CTSO) stock - uspostnews.com
CytoSorbents (CTSO) Stock: Analyst Maintains - GuruFocus
Demystifying CytoSorbents: Insights From 4 Analyst Reviews - Benzinga
FDA denies CytoSorbents’ request for DrugSorb-ATR device - Investing.com
CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR - TipRanks
CytoSorbents (CTSO) Awaits FDA Approval for Breakthrough Device DrugSorb-ATR | CTSO Stock News - GuruFocus
CytoSorbents Provides Regulatory Update for DrugSorb-ATR - PR Newswire
Cytosorbents (NASDAQ:CTSO) versus Microbot Medical (NASDAQ:MBOT) Financial Analysis - Defense World
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights - Longview News-Journal
CytoSorbents, Blood Purification Leader, Reveals Q1 2025 Results and Business Updates May 14 - Stock Titan
CytoSorbents secures $1.7M via NJ tax credit transfer - Investing.com
CytoSorbents Lands $1.7M Strategic Funding: New DrugSorb Product Launch and Manufacturing Expansion Ahead - Stock Titan
U.S. FDA Grants Breakthrough Designation To Cytosorb For Removal Of Ticagrelor During Cardiopulmonary Bypass In Emergent And Urgent Cardiothoracic Surgery - Reuters
Finanzdaten der Cytosorbents Corp-Aktie (CTSO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytosorbents Corp-Aktie (CTSO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MARIANI PETER J | Chief Financial Officer |
Dec 12 '24 |
Buy |
0.89 |
20,000 |
17,872 |
381,363 |
| MARIANI PETER J | Chief Financial Officer |
Dec 11 '24 |
Buy |
0.89 |
11,363 |
10,103 |
361,363 |
0.35%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):